425392-44-5

Basic information

• Product Name: ETHYL 2-BROMO-5-CHLOROTHIAZOLE-4-CARBOXYLATE
• Synonyms: ETHYL 2-BROMO-5-CHLOROTHIAZOLE-4-CARBOXYLATE;2-Bromo-5-chloro-1,3-thiazol-4-carboxylic ethyl ester;Ethyl 2-bromo-5-chloro-1,3-thiazole-4-carboxylate;2-Bromo-5-chloro-4-(ethoxycarbonyl)-1,3-thiazole;2-Bromo-5-chloro-4-thiazolecarboxylic acid ethyl ester;2-(1-(4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazine-1-carbonyl)cyclobutyl)acetic acid;2-Bromo-5-chloro-thiazole-4-carboxylic acid ethyl ester
• CAS NO: 425392-44-5
• Molecular Formula: C₆H₅BrClNO₂S
• Molecular Weight: 270.5314
• Product Categories: Building Blocks;Thiazole
• Mol File: 425392-44-5.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 313℃
• Flash Point: 143℃
• Appearance: /
• Density: 1.749
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -3.22±0.10(Predicted)
• CAS DataBase Reference: ETHYL 2-BROMO-5-CHLOROTHIAZOLE-4-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 2-BROMO-5-CHLOROTHIAZOLE-4-CARBOXYLATE(425392-44-5)
• EPA Substance Registry System: ETHYL 2-BROMO-5-CHLOROTHIAZOLE-4-CARBOXYLATE(425392-44-5)

Safety Data

• Hazardous Substances Data: 425392-44-5(Hazardous Substances Data)

Usage

General Description

ETHYL 2-BROMO-5-CHLOROTHIAZOLE-4-CARBOXYLATE is a chemical compound with the molecular formula C7H6BrClNO2S. It is a derivative of the thiazole ring system and contains both bromine and chlorine atoms. ETHYL 2-BROMO-5-CHLOROTHIAZOLE-4-CARBOXYLATE is primarily used in the pharmaceutical industry as a building block for the synthesis of various pharmaceutical products. Its chemical structure and properties make it suitable for use in the development of new drugs and medications.ETHYL 2-BROMO-5-CHLOROTHIAZOLE-4-CARBOXYLATE is also utilized in academic and research settings for the study of thiazole derivatives and their potential applications in drug development and other fields.

Upstream product

• 136539-01-0 ethyl 2-amino-5-chloro-4-thiazole carboxylate 
• 5398-36-7 2-aminothiazole-4-carboxylate 

Downstream Products

• 425392-48-9 5-chloro-2-(4-methoxy-phenyl)-thiazole-4-carboxylic acid ethyl ester 
• 425392-47-8 5-chloro-2-(2-methoxy-phenyl)-thiazole-4-carboxylic acid ethyl ester 
• 425392-51-4 5-chloro-2-phenylethynyl-thiazole-4-carboxylic acid ethyl ester 
• 59937-01-8 2-phenylthiazole-4-carboxylic acid ethyl ester 
• 425392-45-6 5-chlorothiazole-4-carboxylic acid ethyl ester 
• 425392-46-7 5-chloro-2-phenylthiazole-4-carboxylic acid ethyl ester 
• 1027169-53-4 2-bromo-5-chlorothiazole-4-carboxylic acid 

Relevant articles and documents

Rationally Designed Polypharmacology: α-Helix Mimetics as Dual Inhibitors of the Oncoproteins Mcl-1 and HDM2

Protein–protein interactions (PPIs), many of which are dominated by α-helical recognition domains, play key roles in many essential cellular processes, and the dysregulation of these interactions can cause detrimental effects. For instance, aberrant PPIs involving the Bcl-2 protein family can lead to several diseases including cancer, neurodegenerative diseases, and diabetes. Interactions between Bcl-2 pro-life proteins, such as Mcl-1, and pro-death proteins, such as Bim, regulate the intrinsic pathway of apoptosis. p53, a tumor-suppressor protein, also has a pivotal role in apoptosis and is negatively regulated by its E3 ubiquitin ligase HDM2. Both Mcl-1 and HDM2 are upregulated in numerous cancers, and, interestingly, there is crosstalk between both protein pathways. Recently, synergy has been observed between Mcl-1 and HDM2 inhibitors. Towards the development of new anticancer drugs, we herein describe a polypharmacology approach for the dual inhibition of Mcl-1 and HDM2 by employing three densely functionalized isoxazoles, pyrazoles, and thiazoles as mimetics of key α-helical domains of their partner proteins.

ALKYNYL ALCOHOLS AND METHODS OF USE

The invention relates to compounds of formula (I), wherein Q, A1-A8, R4 and R5 are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.

Synthesis of 2-aryl-oxazolo[4,5-c]quinoline-4(5H)-ones and 2-aryl-thiazolo[4,5-c]quinoline-4(5H)-ones

(Matrix presented) Novel and highly efficient syntheses of oxazolo[4,5-c]quinoline-4(5H)-ones (1) and thiazolo[4,5-c]quinoline-4(5H)-ones (2) from ethyl 2-chlorooxazole-4-carboxylate (4) and ethyl 2-bromo-5-chlorothiazole-4-carboxylate (13), respectively,